Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Treatments

    ... therapy, which can lower your body's immune response Chemotherapy , using drugs that kill abnormal cells Bone marrow ... Chemotherapy If you have ...

    Topic section last updated 08/07/2018 - 2:28pm.

  2. Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes

    ... Intensive chemotherapy for newly diagnosed acute myeloid leukemia (AML) or ... 205 consecutive patients receiving curative-intent induction chemotherapy with cytarabine and an anthracycline ("7+3"; n=175) or a ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

    ... syndromes in complete remission, but post-remission chemotherapy and autologous stem cell transplantation are potential ... evaluated, after intensive anti-leukemic remission-induction chemotherapy, the impact of the availability of an HLA -identical ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.

    Journal Title:  Curr Hematol Malig Rep Primary Author:  Gergis U Author(s):  ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.

    ... syndromes in complete remission (CR) after induction chemotherapy . Sixty patients were enrolled and treated by standard induction chemotherapy. Patients that reached CR started maintenance therapy with ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... Due to their lower toxicity compared to conventional chemotherapy , hypomethylating agents are often a safe and feasible ... may play a role in epigenetic "priming" before conventional chemotherapy. This review summarizes the results of clinical trials and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Transplantation strategies for the management of patients with myelodysplastic syndromes.

    ... are almost equal with the results obtained by intensive chemotherapy alone. Failure was due primarily to TRM in patients with ... the procedure. Autologous SCT after successful induction chemotherapy may increase the proportion of long-term survivors, thus ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System.

    ... care without specific therapy, with AML-like chemotherapy , or with other therapy regimens (low-dose chemotherapy, demethylating agents, immune modulating agents, valproic acid, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents

    ... use of HMAs, add-back strategies, other palliative chemotherapy options, and provide an overview for several promising ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. More is better: Combination therapies for myelodysplastic syndromes

    ... histone deacetylase inhibitors, growth factors, and chemotherapy among others. In this paper we review the current literature ...

    Research Article last updated 07/20/2018 - 5:15pm.